Orthovita, an orthobiologics and biosurgery company, is planning to launch Vitoss Bioactive Foam-2X Bone Graft Substitute (Vitoss BA2X), a non-structural bone void filler for use in the pelvis, extremities and posterolateral spine.

Vitoss BA2X is the first in a series of new product introductions planned by Orthovita that is designed to meet the various bone grafting needs of patients, surgeons and hospitals.

Orthovita president and CEO Antony Koblish said Vitoss BA2X has the same structure and porosity of Vitoss BA but contains increased levels of bioactive glass.

"Our in-vitro data indicate that the increased levels of bioactive glass double the overall bioactivity of the product. Other studies have shown that increasing the bioactivity leads to faster and more abundant bone formation. We believe the combination of increased bioactivity and our unique scaffold design will support more effective bone formation than before," Koblish said.

Vitoss BA2X contains Orthovita’s proprietary Vitoss beta-tricalcium phosphate scaffold and Kensey Nash Corporation’s proprietary collagen material.

Pursuant to its contract with Kensey Nash Corporation, Orthovita will pay Kensey Nash to manufacture the Vitoss BA2X product as well as make certain royalty payments to Kensey Nash based on the net sales of such product.